Gemcitabine

Anti-metabolite

MECHANISM OF ACTION

Inhibits DNA synthesis, pyramide analog

MECHANISM OF KIDNEY INJURY

CLINICAL KIDNEY SYNDROME

HTN, proteinuria, and TMA
myelosuppresion, hyperpigmentation, nail banding, ocular toxicity, MI

CARDIOVASCULAR ADVERSE EFFECTS

LYTE ABNORMALITIES

RISK FACTORS

MITIGATION STRATEGIES

SUGGESTIONS

NOTES/COMMENTS

eGFR < 60 ml/min, no dose adjustment

PHARMACOKINETICS

Molecular Weight

588

Volume of Distribution

Plasma Protein Binding

Metabolism

Bioavailability

Half-life elimination

42-94 mins

Time to peak

Excretion

Gemcitabine <10% urine
metabolites all excreted in urine

Dialyzable?

HD 6-12 hours after drug

REF:

PATHOLOGY SLIDES:

ENTRY UPDATES:

Raad Chowdhury

United States

Sep 25, 2022

PARTNERS WITH